Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -2.85 | -0.38% | 747.0709 | 760.2399 | 745.0812 | 754.00 | 3,843,664 | 01:00:00 |
From Nov 2023 to Nov 2024
By Colin Kellaher
Verve Therapeutics shares fell more than 10% in premarket trading Wednesday after the clinical-stage biotechnology said it was raising about $148 million in a public offering and concurrent private placement.
The Boston company said it is selling 12.5 million shares at $10 apiece in the public offering, below Tuesday's closing price of $11.93.
Verve also said it is selling nearly 2.3 million shares at $10 each to gene-editing partner Eli Lilly, which in June invested $30 million in Verve as part of the partnership.
Shares of Verve, which had around 63.7 million shares outstanding as of Sept. 30, were recently down 12% to $10.49 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 29, 2023 06:32 ET (11:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
